Rafael Holdings, Inc.

NYSE RFL

Rafael Holdings, Inc. Free Cash Flow Yield on February 07, 2025

Rafael Holdings, Inc. Free Cash Flow Yield is NA on February 07, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Rafael Holdings, Inc. 52-week high Free Cash Flow Yield is 105.20% on July 10, 2024, which is NA below the current Free Cash Flow Yield.
Rafael Holdings, Inc. 52-week low Free Cash Flow Yield is -19.72% on August 16, 2024, which is NA below the current Free Cash Flow Yield.
Rafael Holdings, Inc. average Free Cash Flow Yield for the last 52 weeks is 37.22%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NYSE: RFL

Rafael Holdings, Inc.

CEO	Mr. William Conkling
IPO Date	March 27, 2018
Location	United States
Headquarters	520 Broad Street
Employees	13
Sector	Real Estate
Industries Health Care REITs Office REITs

Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key trends

Past 5 years